Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study

Abstract

Purpose: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS). Results: Among 577 patients analyzed, the median age was 56 years and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261–315) and the PFS was 117 days (95% CI: 105–129). Median OS was higher among older patients (≥ 65 vs < 65 years: 325 days [95% CI: 264–385] vs 285 days [95% CI: 252–317]; P = 0.028). Median OS was also higher in patients that received eribulin after fewer prior lines of chemotherapy (≤ 2 vs > 2 prior: 328 days [95% CI: 264–385] vs 264 days [95% CI: 229–298]; P = 0.042). Conclusions: These retrospective data suggest eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings which, while predictable, supports consideration of eribulin as a second-line treatment option.

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

“…A recent real-world study from United Kingdom revealed that patients with TNBC had a significantly worse prognosis than HER2(+)/ER(+) patients when treated with eribulin. 30 The expression of hormone receptors is also an independent factor affecting PFS of patients with ABC. Rossi et al showed that HR(+) patients had almost twice as long PFS as HR(−) patients (mPFS: 2.9 vs. 1.4 months, p = 0.0051).…”

“…For patients in the late-line use group, who had more metastatic sites and received more previous systemic treatments, the mOS was 14.7 months. 12,13,29 Another multicenter retrospective analysis showed that a significantly better mOS for patients with ≤2 previous chemotherapy lines was compared with those with >2 previous chemotherapy lines (328 vs. 264 days), 30 Oruc et al investigated the factors influencing the outcomes of eribulin treatment in 80 patients with MBC who had experienced 3-10 prior lines of treatment. Their multivariate COX analysis revealed that previous systemic treatment line was an independent prognostic factor affecting PFS.…”

“…However, patients with HER2(+) in our study had an obviously inferior mPFS (6.2 months) compared with those reported in previous studies, which may be attributed to that most of HER2(+) patients were heavily pretreated and received eribulin monotherapy. A recent real‐world study from United Kingdom revealed that patients with TNBC had a significantly worse prognosis than HER2(+)/ER(+) patients when treated with eribulin 30 . The expression of hormone receptors is also an independent factor affecting PFS of patients with ABC.…”